Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (POIESIS)
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Sponsor: Kartos Therapeutics, Inc.
Listed as NCT06479135, this PHASE3 trial focuses on MF and Myelofibrosis and remains actively recruiting participants. Sponsored by Kartos Therapeutics, Inc., it has been updated 6 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Oct 2025 — Present [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Jan 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE3
▶ Show 1 earlier version
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
First recorded
Jun 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kartos Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Alessandria, Italy , Amiens, France , Ancona, Italy , Angers, France , Ann Arbor, United States , Antwerp, Belgium , Athens, Greece , Aurora, United States , Aveiro, Portugal and 175 more locations